Deadline: 12-Jun-2026
The Pfizer Research Grant Request for Proposals supports independent clinical and observational research on elranatamab in relapsed or refractory multiple myeloma. It is designed to complement clinical trial data with real-world evidence from routine healthcare practice. The program targets gaps in understanding treatment performance in diverse patient populations, including older adults and those with comorbidities.
Key Objectives of the Program
The program aims to generate real-world evidence on the safety and efficacy of elranatamab in routine clinical use. It focuses on improving understanding of treatment sequencing, especially after therapies such as bispecific antibodies, CAR-T, and antibody-drug conjugates. It also examines immune system recovery, infection risks, and management strategies in long-term treatment settings. Another goal is to evaluate outpatient administration models and their impact on quality of life and healthcare resource use. The program also seeks to identify biomarkers and clinical patterns linked to treatment response and relapse.
Core Research Focus Areas
The grant supports studies in several key areas, including real-world safety and efficacy of elranatamab. It also covers treatment sequencing strategies and the effects of prior therapies on outcomes. Research on immune suppression, infection risks, and immunoglobulin replacement strategies is included. Studies may evaluate outpatient care models and management of side effects such as CRS and ICANS. Additional focus areas include implementation challenges in community settings and identifying biological markers of response or resistance.
Medical Context and Rationale
Relapsed or refractory multiple myeloma remains a major unmet medical need due to increasing treatment resistance and complex sequencing of therapies. While clinical trials demonstrate efficacy, real-world data is needed to understand outcomes in broader patient populations. This includes older patients, individuals with comorbidities, and those treated outside controlled clinical trial environments.
Geographic Scope
The program is open to selected countries, including China, France, Germany, Italy, Japan, Spain, Turkey, and the United Kingdom. Studies may be national or multi-country in design, depending on research objectives and feasibility.
Funding Structure
The grant provides funding for independent research projects with varying budget levels. Typical requests are around $50,000, while standard proposals may request up to $200,000. In cases with strong scientific justification, funding may reach up to $250,000 per study. The program plans to fund up to ten selected research projects.
Eligibility Criteria
Eligible applicants must be organizations based in the listed countries. Applications must be submitted by a Principal Investigator or authorized institutional representative. The Principal Investigator must hold a relevant qualification such as a medical, doctoral, nursing, pharmacy, physiotherapy, or social work degree. The institution must be legally able to receive funding and play an active role in project execution, especially in collaborative studies.
Application Requirements
Applicants must demonstrate strong scientific rationale and a clear research methodology focused on real-world evidence generation. Proposals should include detailed budgets and justification for requested funding. Institutional capacity and collaboration structure must be clearly defined. The study design should align with clinical priorities in multiple myeloma treatment and real-world implementation.
Why This Program Matters
This grant addresses critical gaps between clinical trial data and real-world patient outcomes. It helps improve understanding of how advanced therapies perform in everyday clinical practice. It also supports better treatment sequencing, safer administration strategies, and improved patient quality of life. Ultimately, it contributes to more evidence-based and personalized treatment approaches in multiple myeloma care.
Conclusion
The Pfizer Research Grant program supports high-impact independent research on elranatamab in relapsed or refractory multiple myeloma. By focusing on real-world evidence, it bridges the gap between clinical trials and routine practice. The program strengthens clinical decision-making and improves understanding of treatment outcomes across diverse healthcare systems and patient populations.
For more information, visit Pfizer.